Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | Q9HBH1 | 1/20 | 0.38 | |
| ▸ | MMP2 | P08253 | 5/20 | 0.35 |
| ▸ | MMP3 | P08254 | 5/20 | 0.35 |
| ▸ | MMP1 | P03956 | 3/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.30 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13082195 | 0.86 | EPHX1 (0.35) | PDFMMP2MMP3MMP1MMP7 | |
| SCHEMBL18272869 | 0.80 | MAPT (0.41) | PDFMMP2MMP3MMP1MMP7 | |
| SCHEMBL25634004 | 0.80 | MAPT (0.41) | PDFMMP2MMP3MMP1MMP7 | |
| SCHEMBL19776046 | 0.80 | MAPT (0.41) | PDFMMP2MMP3MMP1MMP7 | |
| SCHEMBL15498413 | 0.77 | ALDH1A1 (0.55) | ALDH1A1PDFMAPT | |
| SCHEMBL26857529 | 0.76 | MAPT (0.36) | ALDH1A1PDFMMP2MMP3MMP1 | |
| SCHEMBL13164473 | 0.74 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL29307836 | 0.72 | MMP2 (0.41) | PDFMMP2MMP3MMP1MMP7 | |
| SCHEMBL21117624 | 0.72 | MMP2 (0.33) | PDFMMP2MMP3MMP1MMP7 | |
| SCHEMBL6729367 | 0.71 | ALDH1A1 (0.59) | ALDH1A1MAPTNAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826432-B2 | Linkers, conjugates and applications thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-11-28 | — | — | US | disclosed |
| US-20220395581-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826432-B2 | Linkers, conjugates and applications thereof | CD44, EPCAM, MSN | ALDH1A1 740/4885PDF 976/4885MMP2 687/4885 |
| US-20220395581-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | CD44, EPCAM, MSN | ALDH1A1 740/4885PDF 976/4885MMP2 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.